瑞帕利单抗-纳武单抗：皮肤科医生实用概述
Relatlimab-nivolumab: A practical overview for dermatologists.
作者信息
Mullick Nikita, Nambudiri Vinod E
机构信息
Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
出版信息
J Am Acad Dermatol. 2023 Nov;89(5):1031-1037. doi: 10.1016/j.jaad.2023.06.024. Epub 2023 Jun 19.
BACKGROUND
Relatlimab is a human anti-lymphocyte activation gene 3 protein antibody approved for the treatment of metastatic or unresectable melanoma in combination with nivolumab, an existing programmed cell death protein 1 inhibitor.
OBJECTIVE
In this article, we review the clinical literature on the efficacy and therapeutic use of the immune checkpoint inhibitor relatlimab in combination with nivolumab for metastatic melanoma.
METHODS
We provide an overview of the mechanism of action, clinical efficacy, and safety profile of relatlimab-nivolumab through a review of recent publications on this emerging therapeutic combination. Ongoing clinical trials studying the use of relatlimab and associated areas of active investigation are also highlighted.
CONCLUSION
This review strives to inform practicing dermatologists on the use of relatlimab-nivolumab as an approved first-line dual checkpoint inhibitor for metastatic melanoma in appropriate clinical cases.
背景
瑞派利单抗是一种人抗淋巴细胞激活基因3蛋白抗体，已被批准与现有的程序性细胞死亡蛋白1抑制剂纳武单抗联合用于治疗转移性或不可切除的黑色素瘤。
目的
在本文中，我们回顾了关于免疫检查点抑制剂瑞派利单抗与纳武单抗联合用于转移性黑色素瘤的疗效和治疗应用的临床文献。
方法
通过回顾有关这种新兴治疗组合的最新出版物，我们概述了瑞派利单抗-纳武单抗的作用机制、临床疗效和安全性。还重点介绍了正在进行的研究瑞派利单抗使用情况的临床试验以及相关的活跃研究领域。
结论
本综述旨在为执业皮肤科医生提供信息，以便在适当的临床病例中使用瑞派利单抗-纳武单抗作为已获批的转移性黑色素瘤一线双检查点抑制剂。
Zotero 插件